Back to results
US 2026/0240806 A1Published application
R-MDMA and S-MDMA TO ASSIST PSYCHOTHERAPY
AssigneeUniversitätsspital Basel
InventorMatthias Emanuel LIECHTI
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeUniversitätsspital Basel
InventorMatthias Emanuel LIECHTI
Estimating the term…
A composition including R-MDMA, S-MDMA, or specific (not 1:1 as in racemic MDMA) combinations of these two enantiomers of racemic MDMA as well as R-MDA, S-MDA, and a combination that is not 1:1 of R-MDA and S-MDA. A method of treating an individual, especially in substance-assisted psychotherapy by administering the composition to the individual. A method of personalized medicine, by evaluating an individual who is in need of MDMA treatment and determining if there are characteristics of the individual present that would not be suitable for MDMA treatment, and administering the composition to the individual. A method of reducing abuse of MDMA by an individual, by administering R-MDMA to the individual and thereby reducing abuse.
A composition comprising an effective amount of a compound chosen from the group consisting of R-MDMA, S-MDMA, a combination that is not 1:1 of R-MDMA and S-MDMA, R-MDA, S-MDA, and a combination that is not 1:1 of R-MDA and S-MDA.
A method of treating an individual, including the steps of:
A method of personalized medicine, including the steps of:
A method of reducing abuse of MDMA by an individual, including the steps of:
Dependencies are inferred from the claim text.